Source - LSE Non-Regulatory
RNS Number : 3363N
Creo Medical Group PLC
07 May 2024

Creo Medical Group plc

("Creo" the "Company" or the "Group")


Creo Medical receives King's Award for Enterprise in Innovation


Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy, announces that it is to receive a King's Award for Enterprise in Innovation, at an event to be held at Windsor Castle on 9 July 2024.


Established by Royal Warrant in 1965, The King's Awards for Enterprise is the UK's most prestigious business awards to recognise and encourage achievements in the fields of Innovation, International Trade, Sustainable Development and Promoting Opportunity through social mobility.


During the reception, His Majesty will meet Creo's Chief Executive Officer, Craig Gulliford, as well as a diverse group of winners from across the United Kingdom, with recipients of the award able to use The King's Awards emblem for the next five years on their products and to promote their services.


A blue building with white text Description automatically generated


Creo Medical Group plc is an innovative and growing medical technology company. It has developed CROMA, an advanced energy electrosurgical platform and a range of novel, miniaturised devices that are used through the small working channels of endoscopes, enabling the most minimally invasive surgery where operations are performed from inside the body. Creo's Speedboat device harnesses CROMA's cutting and coagulation capabilities to remove cancerous and pre-cancerous growths and complex lesions in the bowel, oesophagus and stomach. By providing a solution that reduces the risks associated with conventional surgical procedures, Creo's Speedboat allows clinicians to precisely lift, resect and coagulate tissue with a single device, removing lesions from within the gastrointestinal tract in one piece. This means patients can be treated as day cases under mild sedation instead of more invasive surgery requiring general anaesthetic and multiple days in hospital.


Creo's products deliver benefits to patients, reduce waiting lists, free up resources, and significantly lower hospital costs. NHS Supply Chain recently confirmed net cash savings of £687k were generated for an NHS Trust from 130 procedures using Creo's core Speedboat technology. Creo's technology is patent protected, and its devices are used daily across dozens of countries and in over 20 NHS hospitals.


Craig Gulliford, Chief Executive Officer of Creo Medical, said: "We are delighted to receive this award from His Majesty The King at a Royal reception in recognition of our team's outstanding work, dedication and achievements towards innovation in healthcare. I would like to put on record my thanks to the whole team in their daily commitment to improving patient outcomes, cutting waiting times and saving the NHS money. Innovation has always been at the heart of Creo, and the increasing adoption of our pioneering technology by clinicians around the world, reflects the significant benefits that innovation can bring to both patients and healthcare systems."




Creo Medical Group plc

Richard Rees (CFO)

+44 (0)1291 606 005

Cavendish Capital Markets Limited

+44 (0)20 7397 8900

Stephen Keys / Camilla Hume (NOMAD)

Michael Johnson (Sales)

Deutsche Numis (Joint Broker)

Freddie Barnfield / Duncan Monteith / Euan Brown

+44 (0)20 7260 1000

Walbrook PR

Tel: +44 (0)20 7933 8780 or

Paul McManus / Sam Allen

Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

+44 (0)7867 984 082 


About Creo Medical (

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.


The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

A close-up of a device Description automatically generated


About The King's Award


The King's Awards for Enterprise are the most prestigious awards for UK businesses, previously known as The Queen's Awards for Enterprise. The Awards recognise and celebrate business excellence in innovation, international trade, sustainable development and promoting opportunity (through social mobility). 


Awardees receive a Grant of Appointment and a trophy presented by one of HM Lord-Lieutenants, and are able to display the Award Emblem for up five years. They also have access to a thriving alumni network of previous award winners.


Recipients of the Award often state that their achievement has opened new doors for them in terms of securing new contracts, venturing into new markets, and further developing their business.


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Creo Medical Group PLC (CREO)

-0.25p (-0.75%)
delayed 15:57PM